CVKD: Cadrenal Therapeutics, Inc. Stock

by  •  • Comments Off on CVKD: Cadrenal Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 31.10
Enterprise Value ($M) 21.09
Book Value ($M) 7.44
Book Value / Share 4.17
Price / Book 4.18
NCAV ($M) 7.43
NCAV / Share 4.17
Price / NCAV 4.19

Profitability (mra)
Return on Invested Capital (ROIC) -1.43
Return on Assets (ROA) -1.25
Return on Equity (ROE) -1.38

Liquidity (mrq)
Quick Ratio 3.77
Current Ratio 3.77

Balance Sheet (mrq) ($M)
Current Assets 10.11
Assets 10.12
Liabilities 2.68
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -10.96
Net Income -10.65

Cash Flow Statement (mra) ($M)
Cash From Operations -7.36
Cash from Investing -0.01
Cash from Financing 8.98

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-12 13G/A Havlickova 648 a.s. 4.39 18.03
01-29 13D Pham Quang X 23.60 -93.34
01-15 13G/A Murphy John Raymond 2.96 -92.56
11-14 13G/A Armistice Capital, Llc 4.99 -94.38

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‌ For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-14 10,253 44,200 23.20
2025-03-13 5,649 26,339 21.45
2025-03-12 10,445 55,683 18.76
2025-03-11 12,722 44,025 28.90
2025-03-10 13,953 42,463 32.86

(click for more detail)

Similar Companies
CSCI – COSCIENS Biopharma Inc. CTXR – Citius Pharmaceuticals, Inc.
CUE – Cue Biopharma, Inc. CYCC – Cyclacel Pharmaceuticals, Inc.
CYCN – Cyclerion Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io